川芎嗪注射液联合阿奇霉素序贯治疗大叶性肺炎及迁延性肺炎的临床研究

发布时间：2018-08-03 21:29

【摘要】：目的观察川芎嗪注射液联合阿奇霉素序贯治疗大叶性肺炎及迁延性肺炎的临床疗效及安全性。方法 68例大叶性肺炎及迁延性肺炎患者随机分为对照组34例与试验组34例。对照组在常规治疗的基础上静脉滴注注射用阿奇霉素10 mg·kg~(-1),连用3~5 d,患者体温及外周血白细胞恢复至正常范围,口服阿奇霉素干混悬剂10 mg·kg~(-1),每日1次。试验组在对照组的基础上静脉滴注盐酸川芎嗪注射液40 mg,每日1次。2组患者均治疗10 d。比较2组的临床疗效、血清白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)、T淋巴细胞亚群水平及药物不良反应发生情况。结果治疗后,试验组总有效率为88.24%(30/34例),对照组为64.71%(22/34例,P0.05)。治疗后,对照组和试验组IL-6分别为(40.39±4.87),(21.08±2.90)pg·mL~(-1);IL-8分别为(43.29±5.22),(27.93±3.19)pg·mL~(-1),IL-10分别为(31.93±3.53),(18.02±2.45)pg·mL~(-1),差异有统计学意义(P0.05)。治疗后,对照组和试验组CD3+分别为(63.49±7.41)%,(77.92±8.41)%,CD4~+分别为(30.20±3.58)%,(35.83±4.71)%,CD8~+分别为(27.38±3.49)%,(23.07±3.01)%,CD4~+/CD8~+分别为1.18±0.21,1.32±0.16,差异均有统计学意义(均P0.05)。试验组的药物不良反应有胸闷、轻微胃肠道反应、低血压,药物不良反应发生率为8.82%(3/34例);对照组的药物不良反应有嗜睡、轻微胃肠道反应、胸闷、皮疹,药物不良反应发生率为17.65%(6/34例),差异无统计学意义(P0.05)。结论川芎嗪注射液联合阿奇霉素序贯治疗大叶性肺炎及迁延性肺炎的临床疗效较高,安全性高。
[Abstract]:Objective to observe the clinical efficacy and safety of ligustrazine injection combined with azithromycin in the treatment of lobar pneumonia and persistent pneumonia. Methods 68 patients with lobar pneumonia and persistent pneumonia were randomly divided into control group (34 cases) and trial group (34 cases). On the basis of routine treatment, the patients in the control group were treated with azithromycin 10 mg kg ~ (-1) intravenously for 5 days, and the body temperature and peripheral blood leukocytes returned to normal level. The patients were given azithromycin dry suspension 10 mg kg ~ (-1) once a day. In the experimental group, 40 mg of ligustrazine hydrochloride was injected intravenously on the basis of the control group, and the patients in group 2 were treated for 10 days once a day. The clinical efficacy, serum interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) T lymphocyte subsets and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rate was 88.24% (30 / 34 cases) in the trial group and 64.71% (22 / 34 cases) in the control group (P0.05). After treatment, the IL-6 of the control group and the experimental group were (40.39 卤4.87), (21.08 卤2.90) PG mL ~ (-1) and (43.29 卤5.22), (27.93 卤3.19) PG mL ~ (-1) IL-10, respectively (31.93 卤3.53), (18.02 卤2.45) PG mL ~ (-1) (P0.05). After treatment, the CD3 of the control group and the experimental group were (63.49 卤7.41), (77.92 卤8.41) and (30.20 卤3.58), (35.83 卤4.71) and (27.38 卤3.49), respectively (63.49 卤7.41), (77.92 卤8.41) and (30.20 卤3.58), (35.83 卤4.71), (27.38 卤3.49) and (23.07 卤3.01), respectively. The adverse drug reactions in the trial group were chest tightness, mild gastrointestinal reaction, hypotension, adverse drug reaction rate of 8.82% (3 / 34 cases), and the adverse drug reactions in the control group were somnolence, mild gastrointestinal reaction, chest tightness, rash. The incidence of adverse drug reactions was 17.65% (6 / 34 cases) with no significant difference (P0.05). Conclusion Ligustrazine injection combined with azithromycin is safe and effective in the treatment of lobar pneumonia and persistent pneumonia.
【作者单位】：绍兴市立医院呼吸一科;
【基金】：浙江省医药卫生一般研究计划基金资助项目(2013KYA209)
【分类号】：R563.1

【相似文献】